Intero Biosystems is commercializing lab-grown human intestines as alternatives to animal testing for drugmakers, aligning with growing regulatory pressure. The startup aims to scale production and expand its organoid technology platform.
Background
Regulatory bodies worldwide are increasingly pushing pharmaceutical companies to reduce animal testing, driving demand for alternative models like organ-on-chip and lab-grown tissue technologies.
- Source
- TechCrunch
- Published
- Oct 15, 2026 at 07:00 AM
- Score
- 6.0 / 10